

Haematologica
HAEMATOL/2017/181339
Version 3

Melphalan 140mg/m² or 200mg/m² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Holger W Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H Russell, Jane F Apperley, David Pohlreich, Paul Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christoph Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O Schönland, Curly Morris, Laurent Garderet, and Nicolaus Kröger

Disclosures: The CALM study was sponsored by Genzyme Sanofi and conducted by the EBMT. The sponsor had no involvement in the design or conduct of this subgroup analysis or the writing of the manuscript. NK received honoraria from Sanofi

Contributions: HWA designed the study, analysed data, and wrote the paper. SI, GS, and LK-B analysed data and wrote the paper. All other authors provided patient care, supplied data, and contributed to the study design and writing of the paper.